Back to discover

Protein / target

Leptin

Encoded byLEPP41159Homo sapiensSwiss-Prot
Antibody-tractable
Druggability
UniProt loc high conf
19
Research papers

Protein at a glance

Biological role

Peptide hormone receptor binding

Strongest disease association

Diabetes Mellitus, Type 2

Via encoding gene LEP · Genetic evidence · score 0.69

Research activity

Emerging research

19 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Key player in the regulation of energy balance and body weight control.

View complete UniProt function annotation

Key player in the regulation of energy balance and body weight control. Once released into the circulation, has central and peripheral effects by binding LEPR, found in many tissues, which results in the activation of several major signaling pathways (PubMed:15899045, PubMed:17344214, PubMed:19688109). In the hypothalamus, acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides, also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery, increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic for endothelial cell and affects innate and adaptive immunity (By similarity) (PubMed:11460888, PubMed:19688109, PubMed:24340098, PubMed:25060689, PubMed:8589726). In the arcuate nucleus of the hypothalamus, activates by depolarization POMC neurons inducing FOS and SOCS3 expression to release anorexigenic peptides and inhibits by hyperpolarization NPY neurons inducing SOCS3 with a consequent reduction on release of orexigenic peptides (By similarity). In addition to its known satiety inducing effect, has a modulatory role in nutrient absorption. In the intestine, reduces glucose absorption by enterocytes by activating PKC and leading to a sequential activation of p38, PI3K and ERK signaling pathways which exerts an inhibitory effect on glucose absorption (PubMed:24340098). Acts as a growth factor on certain tissues, through the activation of different signaling pathways increases expression of genes involved in cell cycle regulation such as CCND1, via JAK2-STAT3 pathway, or VEGFA, via MAPK1/3 and PI3K-AKT1 pathways (By similarity) (PubMed:17344214). May also play an apoptotic role via JAK2-STAT3 pathway and up-regulation of BIRC5 expression (PubMed:18242580). Pro-angiogenic, has mitogenic activity on vascular endothelial cells and plays a role in matrix remodeling by regulating the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) (PubMed:11460888). In innate immunity, modulates the activity and function of neutrophils by increasing chemotaxis and the secretion of oxygen radicals. Increases phagocytosis by macrophages and enhances secretion of pro-inflammatory mediators. Increases cytotoxic ability of NK cells (PubMed:12504075). Plays a pro-inflammatory role, in synergy with IL1B, by inducing NOS2 which promotes the production of IL6, IL8 and Prostaglandin E2, through a signaling pathway that involves JAK2, PI3K, MAP2K1/MEK1 and MAPK14/p38 (PubMed:15899045, PubMed:19688109). In adaptive immunity, promotes the switch of memory T-cells towards T helper-1 cell immune responses (By similarity). Increases CD4(+)CD25(-) T-cell proliferation and reduces autophagy during TCR (T-cell receptor) stimulation, through MTOR signaling pathway activation and BCL2 up-regulation (PubMed:25060689)

Subcellular location

Secreted
Domains and Gene Ontology detail (85)

Gene Ontology

  • Ccytosol
  • Cextracellular region
  • Cextracellular space
  • FDNA binding
  • Fhormone activity
  • Fleptin receptor binding
  • Fpeptide hormone receptor binding
  • Pactivation of protein kinase C activity
  • Padult feeding behavior
  • Pangiogenesis
  • Pbone growth
  • Pbone mineralization involved in bone maturation

167 aa · 19 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismGOCell migrationUniProtImmune signallingUniProt · GOKinase signallingGOApoptosis & cell deathGO
View supporting evidence

Lipid & lipoprotein metabolism

  • ·fatty acid catabolic process
  • ·lipid metabolic process
  • ·regulation of lipoprotein lipid oxidation

Cell migration

  • ·Key player in the regulation of energy balance and body weight control. Once released in…

Immune signalling

  • ·Key player in the regulation of energy balance and body weight control. Once released in…
  • ·positive regulation of fat cell apoptotic process
  • ·positive regulation of interleukin-12 production
  • ·positive regulation of interleukin-6 production

Kinase signalling

  • ·activation of protein kinase C activity
  • ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction

Apoptosis & cell death

  • ·negative regulation of apoptotic process
  • ·positive regulation of fat cell apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene LEP

Gene-level evidence surfaced through the gene LEPthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Diabetes Mellitus, Type 2
0.74Moderately supported

Genetic evidence dominant · Open Targets 0.45

Obesity due to melanocortin 4 receptor deficiency
0.47Preliminary

Animal model evidence dominant · Open Targets 0.15 · no direct causal or clinical evidence

Eye Diseases
0.45Limited support

Genetic evidence dominant · Open Targets 0.27

Peptic ulcer disease
0.45Limited support

Genetic evidence dominant · Open Targets 0.27

Duodenal ulcer
0.43Limited support

Genetic evidence dominant · Open Targets 0.26

View evidence synthesis (5)
Diabetes Mellitus, Type 2Moderately supported
0.74
agreement 0.600.88
Genetic82%Literature18%

Open Targets aggregate 0.45 · 2 independent evidence families

Obesity due to melanocortin 4 receptor deficiencyPreliminary
0.47
agreement 0.290.64
Animal model71%Literature29%

Open Targets aggregate 0.15 · 2 independent evidence families · no direct causal or clinical evidence

Eye DiseasesLimited support
0.45
agreement 0.310.59
Genetic99%Literature1%

Open Targets aggregate 0.27 · 2 independent evidence families

Peptic ulcer diseaseLimited support
0.45
agreement 0.310.59
Genetic92%Literature8%

Open Targets aggregate 0.27 · 2 independent evidence families

Duodenal ulcerLimited support
0.43
agreement 0.290.57
Genetic99%Literature1%

Open Targets aggregate 0.26 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Diabetes Mellitus, Type 20.45
Eye Diseases0.27
Peptic ulcer disease0.27
Duodenal ulcer0.26
Obesity due to melanocortin 4 receptor deficiency0.15
Obesity disorder0.14

Tractability

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
AB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas loc

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

weight gainClinPGxextreme weight gainClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

19 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Cummings DE · The New England journal of medicine · 2002

Tschöp M · Diabetes · 2001

Plows JF · International journal of molecular sciences · 2018

Recent

Europe PMC papers linked directly to this protein.